Company Announcements

Exercise of Options, Issue of Equity and TVR

Source: RNS
RNS Number : 5328O
Diurnal Group PLC
08 October 2021
 

8 October 2021

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Exercise of Options, Issue of Equity and Total Voting Rights

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has issued 150,111 new ordinary shares of 5 pence each ("New Ordinary Shares") as a result of an exercise of options under the Company's Long Term Incentive Plan ("LTIP").

 

Application has been made for admission of the 150,111 New Ordinary Shares to trading on AIM, which is anticipated to occur at 8:00am on or around 12 October 2021 ("Admission"). The New Ordinary Shares will rank pari passu with the existing shares of common stock of the Company. Following Admission, the Company's issued ordinary share capital will consist of 169,053,801 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in Diurnal following Admission will be 169,053,801.

 

The above figure of 169,053,801 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0)20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: Rupert Dearden




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

 

Notes to Editors

 

 

About Diurnal Group plc

 

Founded in 2004, Diurnal is a UK-headquartered, European specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUWUARAAURRAA